BioLineRx Launches JV With Hemispherian
BioLineRx (NASDAQ: BLRX, TASE: BLRX), an Israeli clinical-stage biopharmaceutical company, has formed a joint venture with Norway’s Hemispherian AS to develop GLIX1, a first-in-class oral small molecule targeting DNA damage response in glioblastoma and other cancers.
The collaboration aims to accelerate the development of novel oncology treatments through combined scientific and technological resources.
Arnon, Tadmor-Levy advised BioLineRx on the transaction, which involved the negotiation and drafting of complex intellectual property and technology transfer agreements, as well as joint venture structures covering governance, management, and investment. The team included partners Daniel Green, Simon Weintraub, Nataly Margalit, together with associates Leah Grumet, Idan Adar, and Shmulie (Samuel) Kuperstok.
